Blocking IL-6-IL-6R binding leads to acute phase response inhibition, impeding the α-1 antitrypsin (AAT) production and release which has a protective endogenous antiprotease and anti-inflammatory function, increasing the risk of infection [28, 35]. Here, IL6R is linked to infection.